Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
R. Charles Coombes(Imperial College London), Stuart McIntosh(Queen's University Belfast), Paul A. Dickinson, Laura Kenny(Charing Cross Hospital), Edward Ainscow, Rinath Jeselsohn(Dana-Farber Cancer Institute), Simak Ali(The London College), Glen Clack(University of Sheffield), Patrick J. Ward(The US Oncology Network), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sagar Sardesai(The Ohio State University Wexner Medical Center), Zahi Mitri(Oregon Health & Science University), Joyce O’Shaughnessy(Baylor University Medical Center), Matthew Krebs(Christie's), Pavani Chalasani(University of Arizona), William J. Gradishar(Northwestern University), Simon Lord(University of Oxford), Carlo Palmieri(University of Liverpool), Raluca Maria Fostea(Informa Healthcare), Janine Mansi(Guy's and St Thomas' NHS Foundation Trust), Gianflippo Bertelli, Ash Bahl(Loughborough University), Sacha J. Howell(The Christie NHS Foundation Trust)
Cited by 7
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.6k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960